Jaymin Shah
About Jaymin Shah
Jaymin Shah serves as the Executive Director of Clinical Pharmacology at DURECT Corporation, where he has worked since 2006. He has a robust background in drug development and regulatory submissions, with a history of contributing to the approval of several notable medications.
Current Role at DURECT Corporation
Jaymin Shah serves as the Executive Director of Clinical Pharmacology at DURECT Corporation. He has held this position since 2006, accumulating 18 years of experience in this role. His responsibilities include overseeing clinical pharmacology strategies and ensuring the successful development and approval of pharmaceutical products.
Previous Experience in Clinical Pharmacology
Prior to his current role, Jaymin Shah worked at Elan Pharmaceuticals as the Senior Director of Clinical Pharmacology from 1999 to 2002. He also served as the Associate Director of Clinical Pharmacology at ALZA Corporation from 1995 to 1999. His extensive experience in these roles contributed to his expertise in drug development and regulatory processes.
Educational Background in Pharmacy and Pharmacokinetics
Jaymin Shah obtained his Bachelor of Pharmacy (B.Pharm) degree from Karnatak University, where he studied from 1976 to 1980. He furthered his education at Virginia Commonwealth University, earning a degree in Pharmacokinetics from 1981 to 1983. He completed his PhD in Pharmacokinetics at the University of Missouri-Kansas City, studying from 1983 to 1988.
Contributions to Drug Approval and Development
Throughout his career, Jaymin Shah has been instrumental in the approval of several drugs, including Ticlid™, Cellcept™, Testoderm™, Zonegran™, Truvada™, and Posimir™. He possesses extensive experience in global regulatory submissions and has interacted with regulatory bodies such as the US FDA, EMA, and Canada HPB.
Research Publications and Patents
Jaymin Shah has an extensive record of publications and scientific presentations in the field of clinical pharmacology. He contributed to a publication in The American Journal of Gastroenterology, focusing on the safety, pharmacokinetics, and efficacy signals of Larsucosterol in alcohol-associated hepatitis. Additionally, he holds multiple granted patents related to drug development.